FATE — FATE THERAPEUTICS INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1434316 ·
Last close
$2.35
Market Cap
$281.58M
52W High
$3.23
52W Low
$0.95
ADV30
1,541,997
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 2,082,000 | — | -31,134,000 | -30,159,000 | 260,103,000 | 32,429,000 | 106,665,000 |
| Mar 2026 | 1,299,000 | — | -33,000,000 | -31,213,000 | 284,916,000 | 39,570,000 | 105,209,000 |
| Dec 2025 | 1,369,000 | — | -34,721,000 | -32,374,000 | 318,937,000 | 46,628,000 | 111,753,000 |
| Sep 2025 | 1,741,000 | — | -34,735,000 | -32,250,000 | 343,671,000 | 40,622,000 | 109,605,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-103,097,000
Investing CF
$92,080,000
Financing CF
$5,490,000
CapEx
$-4,996,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.09
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,565,522,000
Inventory
—
Receivables
$704,000
ST Investments
$135,252,000
EBIT TTM
$-139,424,000
Pretax Income TTM
$-129,907,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,491,000
EBITDA
$-120,502,000
Free Cash Flow
$-48,659,248
Enterprise Value
$198,693,392
Total Cash
$153,770,000
Total Debt
$75,675,000
Shares Out
119,820,514
Trailing EPS
$-1.05
Book Value
$1.31
ROE
-60.8%
ROA
-26.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,646,000 | -147,704,000 | -136,315,000 | 318,937,000 | 111,753,000 | 207,184,000 | -106,084,000 |
| Dec 2024 | 13,631,000 | -195,539,000 | -186,262,000 | 440,694,000 | 121,968,000 | 318,726,000 | -122,874,000 |
| Dec 2023 | 63,533,000 | -190,511,000 | -160,928,000 | 506,217,000 | 137,800,000 | 368,417,000 | -132,263,000 |
| Dec 2022 | 96,300,000 | -308,386,000 | -281,721,000 | 705,561,000 | 221,622,000 | 483,939,000 | -248,208,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.97
Max Pain — expiry 2026-11-20
max pain strike: $2.00 · spot: $2.39 · call oi: 2,556 · put oi: 604
Expected Move to 2026-11-20:
±$0.75
(31.32%) —
implied range
$1.64 –
$3.14
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IKT | Inhibikase Therapeutics, Inc. | $287.44M | $2.06 | — |
| IVVD | Invivyd, Inc. | $275.30M | $0.93 | — |
| LXEO | Lexeo Therapeutics, Inc. | $271.57M | $3.31 | — |
| XFOR | X4 Pharmaceuticals, Inc | $298.43M | $3.01 | — |
| STRO | SUTRO BIOPHARMA, INC. | $264.97M | $15.98 | — |
News headlines (Yahoo Finance, 1h cache)
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
2026-09-25 11:00 · Yahoo
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
2026-09-03 11:00 · Yahoo
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
2026-08-13 13:45 · Yahoo
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
2026-08-13 12:30 · Yahoo
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-08-03 20:05 · Yahoo
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
2026-07-09 12:30 · Yahoo
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
2026-07-06 12:30 · Yahoo
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
2026-07-01 20:05 · Yahoo
Fate Therapeutics Appoints Laura Hamill to Board of Directors
2026-06-15 12:30 · Yahoo
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
2026-06-04 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.